Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer
- 1 April 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 20 (4), 217-229
- https://doi.org/10.1097/cad.0b013e3283293fd4
Abstract
Capecitabine (N -pentyloxycarbonyl-5-deoxy-5-fluorocytidine), an oral prodrug of 5-fluorouracil, has provided compelling efficacy data for the treatment of metastatic breast cancer and stage III or IV colorectal cancer, both as monotherapy and in combination regimens. The preferential conversion of capecitabine to 5-fluorouracil in neoplastic tissues renders this fluoropyrimidine particularly appealing for clinical use. The enzyme thymidine phosphorylase, which mediates the final step of the capecitabine activation pathway, is expressed in higher concentration in neoplastic than in healthy tissues. This makes capecitabine more tumor specific than other chemotherapeutic agents. Accordingly, capecitabine is generally well tolerated. In particular, the incidence of myelosuppression and alopecia is low, and the most common side effects, hand-foot syndrome and diarrhea, are usually manageable. Given its good toxicity profile, capecitabine was assessed in combination with several chemotherapeutic or biologic agents. In addition, the observation that thymidine phosphorylase is upregulated after treatment with other anticancer drugs, namely taxanes, provided a rationale for the prominent antitumor activity recently observed for the combination of capecitabine with these agents. This review provides an evidence-based update of clinical trials investigating the role of capecitabine in the treatment of breast and colorectal cancer, with special emphasis on pharmacological and safety issues that form the basis of currently used schedules.Keywords
This publication has 115 references indexed in Scilit:
- Capecitabine, Alone and in Combination, in the Management of Patients with Colorectal CancerDrugs, 2008
- Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical TrialsThe Oncologist, 2007
- Prodrug research: futile or fertile?Biochemical Pharmacology, 2004
- Clinical Pharmacokinetics of CapecitabineClinical Pharmacokinetics, 2001
- CapecitabineDrugs, 2001
- CapecitabineDrugs, 1999
- Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.Journal of Clinical Oncology, 1998
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEuropean Journal of Cancer, 1998
- Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.Journal of Clinical Oncology, 1998
- Tumor Selective Delivery of 5-Fluorouracil by Capecitabine, a New Oral Fluoropyrimidine Carbamate, in Human Cancer XenograftsBiochemical Pharmacology, 1998